ASCO 2015: ( DCTH ) Delcath Systems Shows Life-Extending Results Treating Liver Cancer Patients
By The ASCO Post
Posted: 5/31/2015 7:50:52 PM
Clinicians continue to produce positive, life-extending results treating liver cancer patients with CHEMOSAT in multiple tumor types
CHEMOSAT is well tolerated and is an easy-to-learn procedure for an experienced treatment team
Multiple treatment courses of at least four procedures have been shown to be safe and well tolerated while continuing to provide clinical benefit and good quality of life
Reimbursement continues to be covered through individual funding requests Clinicians are encouragedby the potential for CHEMOSAT to treat many tumor types and support the generation of additional data in these potential indications.
bump.. I like this stock.. 50 percent inst. ownership.. plenty of cash.. very nice data.
I'm a buyer- make money
The Fly On The Wall
Breaking News Feed
( BLUE ) After reviewing the abstract highlights, Wedbush reiterates buy target $222.00
just out- good job Leerink. Looked too cheap to ignore from extreme, ridiculous bears, grabbed me some today.
LINK On STOCKTWITS